Johnson & Johnson (JNJ)

118.60
0.03 0.02
NYSE : Health Care
Prev Close 118.57
Day Low/High 0.00 / 0.00
52 Wk Low/High 89.90 / 126.07
Avg Volume 6.91M
Exchange NYSE
Shares Outstanding 2.74B
Market Cap 324.78B
EPS 5.60
P/E Ratio 21.62
Div & Yield 3.20 (2.70%)

Latest News

10 Stocks Billionaire John Paulson Is Buying for 2016

10 Stocks Billionaire John Paulson Is Buying for 2016

Here are 10 stocks hedge fund manager John Paulson has been buying lately, either initiating new stakes or upping his holdings significantly.

Sporting Goods Leveling Field, Which Stocks Say Interest Rates Are Rising: Jim Cramer's Best Blogs

Sporting Goods Leveling Field, Which Stocks Say Interest Rates Are Rising: Jim Cramer's Best Blogs

Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.

J&J: Don't Overpay for Lukewarm Results

J&J: Don't Overpay for Lukewarm Results

Its long-term reputation appears to be supporting the shares far more than they deserve.

These 10 Safe Dividend Stocks for Retirees Can Beat a Bear Market

These 10 Safe Dividend Stocks for Retirees Can Beat a Bear Market

Preserve capital, and pick up safe income from these blue-chip dividend stocks.

Jim Cramer -- Will Interest Rates Rise? Check These 3 Stocks

Jim Cramer -- Will Interest Rates Rise? Check These 3 Stocks

Johnson & Johnson, American Electric Power and Federal Realty say rates are going higher.

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.

7 Safe Dividend Stocks Paying You More Each Year

7 Safe Dividend Stocks Paying You More Each Year

These blue chip stocks have boosted their dividends for at least 40 consecutive years and provide some of the most reliable dividend payments in the market.

Esketamine Receives Breakthrough Therapy Designation From U.S. Food And Drug Administration For Major Depressive Disorder With Imminent Risk For Suicide

Esketamine Receives Breakthrough Therapy Designation From U.S. Food And Drug Administration For Major Depressive Disorder With Imminent Risk For Suicide

FDA action marks second Breakthrough Therapy Designation for intranasal esketamine, highlighting its potential as treatment for patients with major depressive disorder who are at imminent risk for suicide and for those with treatment-resistant depression

Dividend stampede

Dividend stampede

The search for yield isn't easy, given ultra-low rates

Cardinal Health: The Best Dividend Aristocrat to Buy Today

Cardinal Health: The Best Dividend Aristocrat to Buy Today

Cardinal Health (CAH) offers a compelling dividend investment opportunity. Here's why.

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #14 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #289 spot.

Where Will a Healthy Zimmer Biomet Turn Next for Acquisitions?

Where Will a Healthy Zimmer Biomet Turn Next for Acquisitions?

Zimmer's return to growth is fueling acquisition thoughts by analysts. There are a number of possibilities.

Zimmer Biomet and NuVasive Could be a Spine-Tingling Combination

Zimmer Biomet and NuVasive Could be a Spine-Tingling Combination

Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.

Buy Merck on Near-Term Weakness

Buy Merck on Near-Term Weakness

Merck stock has not moved higher. Now is the time to buy.

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

The company's hepatitis C drug division is expected to see losses in the second half of the year.

NYSE, Nasdaq Volume Delivers a Surprise

The net differential for the exchanges caught one off guard.

Top 10 Dividend Aristocrats to Buy at a Discount Now

Top 10 Dividend Aristocrats to Buy at a Discount Now

These 10 dividend aristocrat stocks offer an average high yield of 3% and have increased dividends for 46 consecutive years on average.

Johnson & Johnson Is Getting Rather Expensive

Johnson & Johnson Is Getting Rather Expensive

Time to lock in gains in JNJ.

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.

L'Oréal Will Apply IT Cosmetics for $1.2B

L'Oréal Will Apply IT Cosmetics for $1.2B

A source familiar with the matter said that TSG Consumer Partners earned 25 times its 2013 minority investment in the makeup company.

Don't Disrespect This Bull Market

Don't Disrespect This Bull Market

There are plenty of doubters about the market and its record highs.

Johnson & Johnson (JNJ) Gets Price Target Hike at Deutsche Bank

Johnson & Johnson (JNJ) Gets Price Target Hike at Deutsche Bank

Deutsche Bank upped its price target on Johnson & Johnson (JNJ) stock to $142 from $125 on Thursday morning.

10 Best Dividend Stocks to Own Now for a Safe Retirement

10 Best Dividend Stocks to Own Now for a Safe Retirement

These blue-chip stocks pay safe, generous dividends and form the foundation of a sturdy retirement portfolio.

Valeant's Drug Approvals May Save the Day

Valeant's Drug Approvals May Save the Day

Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.

3 Compelling Reasons to Buy Johnson & Johnson Following Earnings

3 Compelling Reasons to Buy Johnson & Johnson Following Earnings

This health and drug giant is the best in its class. Here is why investors need to load up on J&J stock, which won't disappoint over the long run.

Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles

Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles

Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.